In short
Clinical trials are investigating GS-248 in women with endometriosis. These studies aim to evaluate treatment benefit and safety, especially for endometriosis-related pain. The available trial data describes a Phase 2 study comparing GS-248 with placebo in adult women.
Key points
- Clinical trials are investigating GS-248 in women with endometriosis. The available study is a Phase 2 interventional trial with 300 participants and is currently authorised. It is focused on endometriosis-related pain, including non-menstrual pelvic pain. The main goal is to see whether GS-248 can lower worst pain scores without increasing opioid rescue medicine use. The trial also compares GS-248 with placebo in a blinded capsule form.
Trial overview
The available clinical trial for GS-248 is an interventional study, which means researchers give a study treatment and then measure the results. It is a Phase 2 trial, so it is designed to look more closely at whether the treatment may help and to continue checking safety. The study is authorised and plans to enroll 300 participants.
This trial is being done in women with endometriosis and pain related to that condition. The brief summary says the study aims to evaluate the efficacy of vipoglanstat on endometriosis-related NMPP.
Who can join the study
The trial data says the target population is women with endometriosis. The condition being studied is endometriosis related pain, so the study is focused on people who have pain linked to endometriosis.
NMPP in the trial summary refers to non-menstrual pelvic pain, which means pelvic pain that happens outside the menstrual period. The primary outcome also focuses on non-menstrual days, which helps show whether pain changes when the person is not having a period.
What is being measured
The main endpoint is the proportion of participants who have at least a 2.0-point or at least 30% reduction in the mean worst NMPP NRS score, without an increase in opioid rescue medication use. In simple terms, the study wants to know how many people get a meaningful drop in their worst pain score while not needing more extra pain medicine.
The pain score is measured during non-menstrual days from baseline to the fourth month of treatment. Baseline means the starting point before treatment begins, so the researchers can compare later results with the first measurements.
Study design and treatment groups
The interventions listed in the trial include GS-248, vipoglanstat, and a placebo formulation for GS-248. A placebo is an inactive capsule that looks the same as the real treatment, which helps make the comparison fair.
The trial description says both vipoglanstat capsules and placebo are identical capsules. This suggests the study is designed so participants and researchers may not be able to tell which capsule is being taken just by looking at it.
GS-248 is given orally, which means it is taken by mouth. The source data does not provide more detail about the treatment schedule, so the article focuses only on the information listed in the trial record.
What the trial results may show
If many participants meet the main pain goal, the study may suggest that GS-248 could help reduce endometriosis-related pain in this group. If the pain score does not improve enough, or if more rescue medicine is needed, that would make the treatment look less helpful for this outcome.
Because this is a Phase 2 study, the results are still early and are mainly meant to guide later research. The trial data provided here does not include final results, so the article only describes what the study is designed to test.